E
Shuttle Pharmaceuticals Holdings, Inc. SHPH
$0.39 -$0.0102-2.55%
Recommendation
Sell
Prev Close
$0.39
Volume
86,722
Avg Vol (90D)
125,587
Market Cap
$2.44M
Dividend & Yield
--
52-Week Range
$0.331 - $4.71
P/E (TTM)
--
EPS (TTM)
-$3.79
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
E+
Very Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Very Weak
Dividend Index
--
Headlines
Shuttle Pharmaceuticals Appoints New Interim CEO and CSO
3/31/2025 - TipRanks Financial Blog
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
3/13/2025 - Globe Newswire
Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering
3/12/2025 - Globe Newswire
Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities
3/12/2025 - Globe Newswire
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Up 176.3% in February
2/28/2025 - Ticker Report
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
2/26/2025 - Globe Newswire
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Shuttle Pharmaceuticals Holdings Inc
2/15/2025 - GuruFocus
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
1/21/2025 - Globe Newswire
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
1/7/2025 - Globe Newswire
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
12/19/2024 - Globe Newswire
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
11/26/2024 - Globe Newswire
Shuttle Pharma Provides Third Quarter 2024 Corporate Update
11/13/2024 - Globe Newswire
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
10/30/2024 - Globe Newswire
Shuttle Pharma Pays Off Senior Secured Convertible Note
10/29/2024 - Globe Newswire
Micro Cap Soaring On Phase 2 Trial Update
10/29/2024 - Invezz News
Shuttle Pharmaceuticals Advances Phase 2 Glioblastoma Trial
10/29/2024 - TipRanks Financial Blog
Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
10/29/2024 - Globe Newswire
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
10/28/2024 - Globe Newswire
Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024
10/28/2024 - Globe Newswire
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Update
9/27/2024 - Ticker Report
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
9/16/2024 - Globe Newswire
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
9/11/2024 - Accesswire
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
9/11/2024 - Accesswire
Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
9/5/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$7.69M
EBIT (TTM)
-$7.70M
Net Income (TTM)
-$9.14M
Balance Sheet
Total Assets (Q)
$2.51M
Total Debt (Q)
$1.17M
Total Liabilities (Q)
$1.80M
Book Value Per Share (Q)
$0.174
Cash Flow
Cash from Operations (TTM)
-$7.33M
Cash from Investing (TTM)
$2.92M
Cash from Financing (TTM)
$3.76M
Net Change in Cash (TTM)
-$656.20K
Filings
Filing Date
Wednesday, February 26, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Sep 1 and 5 (est)
Price History
Loading...
Beta
0.58
7-Day Total Return
-1.24%
30-Day Total Return
-36.38%
60-Day Total Return
-54.60%
90-Day Total Return
-55.22%
Year to Date Total Return
-54.17%
1-Year Total Return
-88.59%
2-Year Total Return
-96.64%
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Mar 17, 2025 - $0.331
52-week High
May 31, 2024 - $4.71
Valuation
Market Cap
$2.44M - Nano Cap
Enterprise Value
$1.69M
Price/Sales (TTM)
--
Price/Book (Q)
2.24
Dividends and Shares
Shares Outstanding
4.91M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.shuttlepharma.com
Phone Number
240 403 4212
Address
401 Professional Drive
Gaithersburg, MD 20879
Country
United States
Year Founded
2012
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine... more
NASDAQ 04/04/2025 3:59PM Eastern Quotes delayed
Weiss Ratings